They Sold Their Company to Boston Scientific and Then Reacquired the Technology Years Later: The Unique Story of NuCryo Vascular

Interview with Kevin Beedon

Because of diminishing margins, a lot of major medical device companies continue to add products to their sales bag in hopes of meeting top-line revenue goals. But selling the entire bag is challenging.

When the bag gets too big, a typical sales force will usually focus only on products that generate the most revenue. So what happens to those products that don’t produce much revenue? Well, they’re sometimes just lost in the dust.

In this interview with Kevin Beedon, General Manager of NuCryo Vascular, we learn how their team is taking advantage of this very scenario as they look to commercialize the newly redesigned PolarCath device.

Interview Highlights with Kevin Beedon

  • Why the founders of NuCryo Vascular decided to reacquire the technology they originally sold to Boston Scientific just years earlier.
  • After initially signing a distribution deal with Vascular Solutions, why the team at NuCryo Vascular decided to go with a direct sales force instead.
  • How the team at NuCryo Vascular was able to quickly make engineering changes to the PolarCath device and then get FDA approval only 40 days later
  • Kevin’s advice for making career changes within the medical device space.
  • Kevin’s favorite business book, the business leader he most admires, and the advice he’d give to his 30-yr. old self.
Guest
Kevin Beedon
General Manager of NuCryo Vascular

Kevin Beedon is the General Manager and Vice President of NuCryo Vascular, a subsidiary of Gemini Interventional Technologies. Prior to his role at NuCryo, Kevin has held sales and marketing leadership positions for companies like Spectranetics, Boston Scientific, and Pfizer. Kevin received a MBA in finance from Central Michigan University and a B.S. in chemical engineering from Michigan State.

Download a copy of the interview transcript right here.
Share:
Twitter
Facebook
LinkedIn
Email

Because of diminishing margins, a lot of major medical device companies continue to add products to their sales bag in hopes of meeting top-line revenue goals. But selling the entire bag is challenging.

When the bag gets too big, a typical sales force will usually focus only on products that generate the most revenue. So what happens to those products that don’t produce much revenue? Well, they’re sometimes just lost in the dust.

In this interview with Kevin Beedon, General Manager of NuCryo Vascular, we learn how their team is taking advantage of this very scenario as they look to commercialize the newly redesigned PolarCath device.

Interview Highlights with Kevin Beedon

  • Why the founders of NuCryo Vascular decided to reacquire the technology they originally sold to Boston Scientific just years earlier.
  • After initially signing a distribution deal with Vascular Solutions, why the team at NuCryo Vascular decided to go with a direct sales force instead.
  • How the team at NuCryo Vascular was able to quickly make engineering changes to the PolarCath device and then get FDA approval only 40 days later
  • Kevin’s advice for making career changes within the medical device space.
  • Kevin’s favorite business book, the business leader he most admires, and the advice he’d give to his 30-yr. old self.
Guest
Kevin Beedon
General Manager of NuCryo Vascular

Kevin Beedon is the General Manager and Vice President of NuCryo Vascular, a subsidiary of Gemini Interventional Technologies. Prior to his role at NuCryo, Kevin has held sales and marketing leadership positions for companies like Spectranetics, Boston Scientific, and Pfizer. Kevin received a MBA in finance from Central Michigan University and a B.S. in chemical engineering from Michigan State.

Download a copy of the interview transcript right here.
Share:
Twitter
Facebook
LinkedIn
Email

You May Like These Articles

Premium

Grit and the Power of Showing Up

Interview with Venture Capitalist Anish Kaushal

Anish Kaushal, a former physician turned healthcare investor and author, shares his unconventional career journey from medicine to VC at Amplitude Ventures. He reveals vital fundraising strategies from an investor's perspective, offers practical tips for crafting pitch decks that capture attention, discusses why always being in the mode of seeking funds is so important, expands on the value of building extensive networks, and talks about the cumulative effect of small improvements. He also provides guidance on staying open and ready for career shifts in today’s fast-paced professional environment as outlined in his latest book.

Premium

Collaborating for Clinical Credibility

Interview with Strados Labs CEO Nick Delmonico

In this interview Nick Delmonico, the CEO of Strados Labs, a company developing a wearable stethoscope to remotely capture lung sounds, discusses how Strados validated its technology through others' research and how starting with a clear understanding of the problem, rather than jumping straight to offering solutions, created significant opportunities for his company. Nick also emphasizes why interpersonal skills and active listening are crucial to success in medtech, and shares strategies for non-dilutive funding as a way to alleviate initial capital constraints while building credibility at the same time.

Premium

Medsider Mentors

Volume VI

In Medsider Mentors Volume VI, we’ve distilled key insights from founders and CEOs of some of the hottest medical device and health technology startups including LimFlow, Field Medical, Sinaptica, Spark Biomedical, InterShunt and many more.

View More Interviews
See the Playbooks

Join Medsider as a Free Subscriber

Subscribe to Medsider and get access to exclusive benefits for free. No spam, 100% privacy, and your email won’t be shared.